Towards a hit for every target

Nature Reviews Drug Discovery

Volumn 15, Issue 1, 2016, Pages 1-2

  Rees, Steve ^a   Gribbon, Philip ^b   Birmingham, Karen ^a   Janzen, William P ^c   Pairaudeau, Garry ^a  

^a ASTRAZENECA   (United Kingdom)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PEPTIDE; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA;

COST BENEFIT ANALYSIS; DRUG INDUSTRY; HIGH THROUGHPUT SCREENING; HUMAN; MASS SPECTROMETRY; METABOLOMICS; ORGANIZATION AND MANAGEMENT; PHENOTYPE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROTEOMICS; QUALITY CONTROL; REVIEW; SCIENTIST; TRANSCRIPTOMICS; DRUG DEVELOPMENT; PROCEDURES; PUBLIC-PRIVATE PARTNERSHIP;

DRUG DISCOVERY; DRUG INDUSTRY; HIGH-THROUGHPUT SCREENING ASSAYS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84955216770     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.19     Document Type: Review

References (4)

1. Macarron, R. et al. Impact of high throughput screening in biomedical research. Nat. Rev. Drug. Discov. 10, 188-195 (2011).
2. Cook, D. et al. Lessons learned from the fate of AstraZenecas drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014).
3. Bakken, G. A. et al. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. J. Chem. Inf. Model. 52, 2937-2949 (2012).
4. Simpson, P. B. & Reichman, M. Opening the lead generation toolbox. Nat. Rev. Drug Discov. 13, 3-4 (2014).